Back to Search Start Over

Histiocytic Neoplasms, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology.

Authors :
Go RS
Jacobsen E
Baiocchi R
Buhtoiarov I
Butler EB
Campbell PK
Coulter DW
Diamond E
Flagg A
Goodman AM
Goyal G
Gratzinger D
Hendrie PC
Higman M
Hogarty MD
Janku F
Karmali R
Morgan D
Raldow AC
Stefanovic A
Tantravahi SK
Walkovich K
Zhang L
Bergman MA
Darlow SD
Source :
Journal of the National Comprehensive Cancer Network : JNCCN [J Natl Compr Canc Netw] 2021 Nov; Vol. 19 (11), pp. 1277-1303.
Publication Year :
2021

Abstract

Histiocytic neoplasms are rare hematologic disorders accounting for less than 1% of cancers of the soft tissue and lymph nodes. Clinical presentation and prognosis of these disorders can be highly variable, leading to challenges for diagnosis and optimal management of these patients. Treatment often consists of systemic therapy, and recent studies support use of targeted therapies for patients with these disorders. Observation ("watch and wait") may be sufficient for select patients with mild disease. These NCCN Guidelines for Histiocytic Neoplasms include recommendations for diagnosis and treatment of adults with the most common histiocytic disorders: Langerhans cell histiocytosis, Erdheim-Chester disease, and Rosai-Dorfman disease.

Details

Language :
English
ISSN :
1540-1413
Volume :
19
Issue :
11
Database :
MEDLINE
Journal :
Journal of the National Comprehensive Cancer Network : JNCCN
Publication Type :
Academic Journal
Accession number :
34781268
Full Text :
https://doi.org/10.6004/jnccn.2021.0053